Search research articles
Contact Us
Filters
Showing results (221-230 of 266) with videos related to
Page
of 27
Sort By:
European Urology
|
June 5, 2023
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study
Wassim Abida, David Campbell, Akash Patnaik, et al.
International Journal of Oncology
|
November 20, 2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review
William K Oh, David McDermott, Camillo Porta, et al.
Nature Communications
|
May 7, 2026
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial
Padmanee Sharma, Michael Krainer, Fred Saad, et al.
Cancers
|
June 24, 2022
Genome-Wide Meta-Analysis Identifies Variants in <i>DSCAM</i> and <i>PDLIM3</i> That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
Meta H M Diekstra, Jesse J Swen, Loes F M van der Zanden, et al.
The Lancet. Oncology
|
September 24, 2020
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Thomas Powles, Michiel S van der Heijden, Daniel Castellano, et al.
Nature Medicine
|
July 5, 2019
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
Cristina Segovia, Edurne San José-Enériz, Ester Munera-Maravilla, et al.
Journal for Immunotherapy of Cancer
|
August 17, 2022
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
Karim Fizazi, Margitta Retz, Daniel P Petrylak, et al.
Scientific Reports
|
January 25, 2017
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
Arancha Cebrián, Teresa Gómez Del Pulgar, María José Méndez-Vidal, et al.
European Urology
|
May 16, 2022
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
Bernadett Szabados, Mark Kockx, Zoe June Assaf, et al.
The Oncologist
|
October 6, 2025
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey
Enrique Grande, Joaquim Bellmunt, Syed A Hussain, et al.
Page
of 27
Search research articles
Search
Showing results (221-230 of 266) with videos related to
Sort By:
Page
of 27
European Urology
|
June 5, 2023
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study
Wassim Abida, David Campbell, Akash Patnaik, et al.
International Journal of Oncology
|
November 20, 2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review
William K Oh, David McDermott, Camillo Porta, et al.
Nature Communications
|
May 7, 2026
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial
Padmanee Sharma, Michael Krainer, Fred Saad, et al.
Cancers
|
June 24, 2022
Genome-Wide Meta-Analysis Identifies Variants in <i>DSCAM</i> and <i>PDLIM3</i> That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
Meta H M Diekstra, Jesse J Swen, Loes F M van der Zanden, et al.
The Lancet. Oncology
|
September 24, 2020
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Thomas Powles, Michiel S van der Heijden, Daniel Castellano, et al.
Nature Medicine
|
July 5, 2019
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
Cristina Segovia, Edurne San José-Enériz, Ester Munera-Maravilla, et al.
Journal for Immunotherapy of Cancer
|
August 17, 2022
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
Karim Fizazi, Margitta Retz, Daniel P Petrylak, et al.
Scientific Reports
|
January 25, 2017
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
Arancha Cebrián, Teresa Gómez Del Pulgar, María José Méndez-Vidal, et al.
European Urology
|
May 16, 2022
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
Bernadett Szabados, Mark Kockx, Zoe June Assaf, et al.
The Oncologist
|
October 6, 2025
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey
Enrique Grande, Joaquim Bellmunt, Syed A Hussain, et al.
Page
of 27